Romański B, Gawrońska-Ukleja E, Pawlik K
Katedry i Kliniki Alergologii i Chorób Wewnetrznych AM, Bydgoszczy.
Pneumonol Alergol Pol. 1993;61(3-4):127-32.
The results of a 5-year studies on the therapeutical efficiency of Catalet--desensitization vaccine containing grass pollen antigens adsorbed on aluminium hydroxide--are discussed. Catalet vaccine is manufactured by Sera and Vaccines Works in Kraków in the doses of 25 PNU/ml, 250 PNU/ml, 2500 PNU/ml, and 10,000 PNU/ml. It was found that Catalet possesses a strong antigenic properties and enables complete or partial intensivity to grass pollens in the majority of treated patients. Therapeutical efficiency of Catalet has markedly been different than that of placebo, and had expressed fully following a two- or three-year treatment.
讨论了一项为期5年的关于Catalet（一种含有吸附在氢氧化铝上的草花粉抗原的脱敏疫苗）治疗效果的研究结果。Catalet疫苗由克拉科夫的血清和疫苗厂生产，剂量分别为25 PNU/ml、250 PNU/ml、2500 PNU/ml和10000 PNU/ml。结果发现，Catalet具有很强的抗原特性，能使大多数接受治疗的患者对草花粉产生完全或部分的致敏强度降低。Catalet的治疗效果与安慰剂明显不同，在经过两到三年的治疗后充分显现。
